- Home
- ANIX vs CBAT Comparison
ANIX vs CBAT Comparison
Compare ANIX & CBAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- CBAT
- Stock Information
- Founded
- ANIX 1982
- CBAT 1999
- Country
- ANIX United States
- CBAT China
- Employees
- ANIX N/A
- CBAT N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- CBAT Industrial Machinery/Components
- Sector
- ANIX Health Care
- CBAT Miscellaneous
- Exchange
- ANIX Nasdaq
- CBAT Nasdaq
- Market Cap
- ANIX 82.7M
- CBAT 78.7M
- IPO Year
- ANIX 1987
- CBAT N/A
- Fundamental
- Price
- ANIX $2.41
- CBAT $0.89
- Analyst Decision
- ANIX Strong Buy
- CBAT
- Analyst Count
- ANIX 2
- CBAT 0
- Target Price
- ANIX $8.50
- CBAT N/A
- AVG Volume (30 Days)
- ANIX 121.1K
- CBAT 1.2M
- Earning Date
- ANIX 01-10-2025
- CBAT 03-14-2025
- Dividend Yield
- ANIX N/A
- CBAT N/A
- EPS Growth
- ANIX N/A
- CBAT N/A
- EPS
- ANIX N/A
- CBAT 0.12
- Revenue
- ANIX N/A
- CBAT $207,423,403.00
- Revenue This Year
- ANIX N/A
- CBAT $0.46
- Revenue Next Year
- ANIX N/A
- CBAT $13.78
- P/E Ratio
- ANIX N/A
- CBAT $7.38
- Revenue Growth
- ANIX N/A
- CBAT 2.32
- 52 Week Low
- ANIX $2.07
- CBAT $0.77
- 52 Week High
- ANIX $5.09
- CBAT $2.08
- Technical
- Relative Strength Index (RSI)
- ANIX 44.08
- CBAT 45.53
- Support Level
- ANIX $2.07
- CBAT $0.85
- Resistance Level
- ANIX $2.69
- CBAT $1.11
- Average True Range (ATR)
- ANIX 0.19
- CBAT 0.10
- MACD
- ANIX 0.03
- CBAT -0.01
- Stochastic Oscillator
- ANIX 54.84
- CBAT 10.16
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization and distribution of a variety of standard and customized lithium-ion high-power rechargeable batteries. The company operates in two operating segments: CBAK's segment mainly includes the manufacture, commercialization and distribution of a wide variety of standard and customized lithium ion rechargeable batteries for use in a wide array of applications. Hitrans' segment mainly includes the development and manufacturing of NCM precursor and cathode materials. Geographically, it generates a majority of its revenue from Mainland China and also has an operation in Europe, the United States, Korea, and Other Countries.